



Helping patients who are unable to swallow their medication with innovative functional chewing gum solutions

Alterola Biotech Inc. is creating novel therapeutic delivery systems for everyday ailments, helping people who are unable to be treated by conventional methods.

Studies have shown that as many as 40% of American adults suffer from an inability to swallow pills. As 4 out of 5 common ailments like headaches, muscle pains, allergies, inflammations and the like are treated by pills, this is a very big and overlooked issue. Some people merely suffer from some discomfort when trying to swallow their pills but as many as 14% delay taking their dosage, 8% skip a dose, and 4% stop taking their medication altogether. That is, they simply have to endure excruciating pains, debilitating allergies or potentially life-threatening inflammations!

Alterola Biotech is continually developing new solutions for the significant amount of people who would otherwise have to accept severe discomfort on a regular basis. With Alterola Biotech's functional chewing gum, they can battle all of the everyday discomforts, ailments and diseases that they have previously had to simply endure.

Alterola Biotech is tapping into a huge market with its functional chewing gums. The market for functional chewing gum is at the moment worth more than \$700 million and it is increasing at a steady 15% per annum. However, this market covers only nicotine and dental chewing gum, and does not take into account the huge market there would be for a painkiller or antihistamine chewing gum. In short, Alterola Biotech is going to expand the potential market radically. A measly 1% share of the painkiller market, which is presently at \$24.3 billion, would account for \$243 million in revenues! The entire pharmaceutical market is a whopping \$675 billion. The additional market from being able to offer medicine to those people unable to swallow pills could be as huge as \$33.7 billion!

Alterola Biotech has a number of unique drug patent targets and several more blockbuster drug targets in the pipeline. When it becomes evident exactly how huge the market for Alterola's functional chewing gum is, it is sure to whip up a frenzy in the biotech industry, rewarding investors with three-figure gains!

